Aripiprazole – theory and practice Review article
Article Sidebar
Published:
Sep 30, 2022
Keywords:
aripiprazole, schizophrenia, bipolar affective disorder, monotherapy, safety
Main Article Content
Abstract
Aripiprazole is one of the second-generation, or atypical, antipsychotics that has been known for more than a dozen years. Aripiprazole has a unique receptor profile relative to other antipsychotics, which is reflected in its therapeutic effect and tolerability profile. It acts as an antagonist in situations of dopamine excess, while at low dopamine concentrations it exhibits agonist properties. As numerous studies show, depending on the dose, aripiprazole is effective in the treatment of schizophrenia and bipolar affective disorder in both exacerbation and maintenance therapy. It is also a drug often used in polytherapy. This article provides an overview of the use of aripiprazole in monotherapy, which should become routine practice in the treatment of psychiatric disorders.
Article Details
How to Cite
Szulc, A. (2022). Aripiprazole – theory and practice. Medycyna Faktow (J EBM), 15(3(56), 368-374. https://doi.org/10.24292/01.MF.0322.16
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015; 29(9): 773-99.
2. Seelman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1(2): 133-52.
3. Hart XM, Schmitz CN, Grunder G. Molecular Imaging of Dopamine Partial Antagonists in Humana: Implications for Clinical Practice. Front Psychiatry. 2022; 13: 832209.
4. Chrzanowski WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259-66.
5. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635-47.
6. ABILIFY. Charakterystyka produktu leczniczego.
7. Szulc A, Więdlocha M, Marcinowicz P. Arypiprazol. Via Medica, Gdańsk 2018.
8. Sparshatt A, Taylor D, Patel MX et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447-56.
9. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6: 325-37.
10. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202): 939-51.
11. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta- analysis. Lancet. 2013; 382(9896): 951-62.
12. Ribeiro ELA, Mendonça Lima T, Vieira MEB et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74: 1215-33.
13. Szulc A, Więdlocha M. Arypiprazol – częściowy agonizm, pełna skuteczność. Psychiatria. 2017; 14(1): 1-6.
14. Szulc A. Arypiprazol – monoterapia? Psychiatria. 2020; 17(1): 29-35.
15. Suppes T, Eudicone J, McQuade R et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Affect Disord. 2008; 107(1-3): 145-54.
16. Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013; (12): CD005000.
17. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. 2016; 8(4): e562.
18. Li DJ, Tseng PT, Stubbs B et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79: 289-301.
19. Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2017; 22(2): 177-85.
20. Betzler F, Stöver LA, Sterzer P et al. Mixed states in bipolar disorder – changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21(4): 244-58.
21. Chakrabarty T, Keramatian K, Yatham LN. Treatment of Mixed Features in Bipolar disorder: An Updated Review. Cur Psych Rep. 2020; 22: 15-9.
22. Arypiprazol – charakterystyka produktu leczniczego FDA (access: 25.11.2016).
23. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. 2nd ed. Via Medica, Gdańsk 2015.
24. Poyurovsky M, Bergman J, Pashinian A et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014; 29(5): 296-8.
25. Citrome L, Eramo A, Francois C et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095-104.
26. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386-92.
2. Seelman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1(2): 133-52.
3. Hart XM, Schmitz CN, Grunder G. Molecular Imaging of Dopamine Partial Antagonists in Humana: Implications for Clinical Practice. Front Psychiatry. 2022; 13: 832209.
4. Chrzanowski WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259-66.
5. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635-47.
6. ABILIFY. Charakterystyka produktu leczniczego.
7. Szulc A, Więdlocha M, Marcinowicz P. Arypiprazol. Via Medica, Gdańsk 2018.
8. Sparshatt A, Taylor D, Patel MX et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447-56.
9. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6: 325-37.
10. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202): 939-51.
11. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta- analysis. Lancet. 2013; 382(9896): 951-62.
12. Ribeiro ELA, Mendonça Lima T, Vieira MEB et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74: 1215-33.
13. Szulc A, Więdlocha M. Arypiprazol – częściowy agonizm, pełna skuteczność. Psychiatria. 2017; 14(1): 1-6.
14. Szulc A. Arypiprazol – monoterapia? Psychiatria. 2020; 17(1): 29-35.
15. Suppes T, Eudicone J, McQuade R et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Affect Disord. 2008; 107(1-3): 145-54.
16. Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013; (12): CD005000.
17. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. 2016; 8(4): e562.
18. Li DJ, Tseng PT, Stubbs B et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79: 289-301.
19. Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2017; 22(2): 177-85.
20. Betzler F, Stöver LA, Sterzer P et al. Mixed states in bipolar disorder – changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21(4): 244-58.
21. Chakrabarty T, Keramatian K, Yatham LN. Treatment of Mixed Features in Bipolar disorder: An Updated Review. Cur Psych Rep. 2020; 22: 15-9.
22. Arypiprazol – charakterystyka produktu leczniczego FDA (access: 25.11.2016).
23. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. 2nd ed. Via Medica, Gdańsk 2015.
24. Poyurovsky M, Bergman J, Pashinian A et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014; 29(5): 296-8.
25. Citrome L, Eramo A, Francois C et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095-104.
26. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386-92.